Lynk Pharmaceuticals expands commercialization rights for zemprocitinib
2 reports, 1 independent
Updated Mon 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lynk Pharmaceuticals announced an expansion of its commercialization collaboration for zemprocitinib, a selective, oral, second-generation JAK1 inhibitor. Under the expanded partnership, exclusive commercialization rights were granted for zemprocitinib in Chinese Mainland, Macau, Hong Kong, and Taiwan for moderate-to-severe atopic dermatitis and other dermatology indications.
From prnewswire.com
Why it matters
The expanded agreement builds upon a prior collaboration established in 2022 for rheumatology and immunology indications. This partnership is expected to enhance the market development efficiency and patient access of zemprocitinib within the dermatology sector.
From prnewswire.com
Who's involved
- LynkExpanded commercialization collaboration for the drug zemprocitinib
Keep exploring
The entities involved
-
Lynk
company
Nothing else this week.